Peptides Through Telehealth: What a Temporary Compounding Policy Would Mean for You

If FDA lets pharmacies temporarily compound BPC-157 and similar peptides, you may soon be offered them through an online consultation. That would make them easier to get legally, but it would not make them FDA-approved, and it would not create the human safety and effectiveness data that is still missing. As of 26 October 2026, the policy is still under White House review and its text has not been published.¹²

FDA sent a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Management and Budget (OMB) on 14 October 2026.¹ The Associated Press reported, citing two people familiar with the plan, that it "is intended to allow pharmacies to temporarily compound some of the most popular peptides, including BPC-157," and that telehealth companies Hims & Hers and Noom "recently announced plans to offer peptides to their customers if the federal government eases access."² OMB's records list six meetings that outside groups asked for while it reviews the policy, running from 21 to 28 October 2026. They include the American Academy of Peptide Medicine, Hims & Hers, the Alliance for Pharmacy Compounding and the consumer group Center for Science in the Public Interest.¹

Our explainer on the HHS plan covers the policy itself and how it got here. This guide is for readers: what would change for you, what would not, and what to ask before anyone prescribes a peptide. It is not medical or legal advice and contains no dosing information.

The short version

• Not yet in force. As of 26 October 2026, OMB lists the interim access policy as a pending review. Which peptides, which forms and which conditions it covers are all unknown.¹²
• Compounded is not approved. FDA states that "compounded drugs are not FDA-approved" and that it "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."⁵
• The evidence has not changed. A 2026 systematic review found only three small human studies of BPC-157, with 30 people in total, and rated the certainty of evidence "very low."⁹
• The pharmacy matters. Under federal law, compounding is done by a licensed pharmacist in a state-licensed pharmacy, for an identified patient with a valid prescription. You can ask who that pharmacy is.⁴
• Watch the marketing. In 2026 FDA warned 30 telehealth companies over compounded GLP-1 advertising that implied "sameness with FDA-approved products" or obscured which pharmacy made the drug.¹¹
• Report side effects. FDA's own reviewers noted that pharmacies that compound for individual patients "generally do not report adverse events to FDA", so reports from patients and clinicians matter.⁷¹²

What a temporary policy would and would not change

What could change

Today, a pharmacy can only compound with a bulk ingredient that has a USP or National Formulary monograph, is part of an FDA-approved drug, or appears on a list FDA creates through regulations, the 503A Bulks List.⁴ None of the peptides an FDA advisory committee voted on in July 2026 meets those conditions, and adding any of them to the list requires formal rulemaking.²⁶ The AP reported that "it was not immediately clear if the administration still plans to pursue that process."²

An interim policy would most likely work through enforcement discretion: FDA saying it does not intend to act against certain compounding while conditions are met. Pharmacy groups have asked FDA for exactly that: "interim enforcement discretion."³ FDA has used this approach before. Its January 2025 interim policy for substances under review required, among other things, an FDA-registered ingredient manufacturer and a valid certificate of analysis.¹³ Whether the new policy uses similar conditions is not known.

In practice, that could mean a clinician, including one you see by video, could write a prescription and a state-licensed pharmacy could fill it, rather than people buying vials labelled "research use only" from websites.

What would not change

• Approval status. A stopgap is a decision about enforcement, not a finding that a peptide is safe or works. FDA's briefing documents for the July meeting proposed that none of the seven peptides reviewed be added to the compounding list.⁶⁷ See FDA-approved vs unapproved peptides.
• The evidence. The human studies are the same small, uncontrolled studies they were before.⁹¹⁰
• Pre-market checks. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.⁵
• Sport rules. BPC-157 is banned at all times under anti-doping rules, and those rules do not follow FDA policy.¹⁰ See WADA peptide rules.
• The grey market. A stopgap for pharmacies would not make "research use only" products legal for people to use. Our guide to research-use-only labels explains why.

Which peptides might be covered, and what the evidence shows

No official list exists. BPC-157 is the only peptide named in reporting on the plan.² The most likely candidates are the six the advisory committee recommended in July 2026, against the advice of FDA's own staff: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. Our panel-vote explainer sets out each vote.

BPC-157

BPC-157 has been studied most, almost entirely in animals. A 2026 systematic review searched for every human study up to 1 June 2026 and found three: a retrospective study of knee injections in 16 people, a retrospective pilot in 12 people with interstitial cystitis, and a safety pilot in 2 people. All reported improvement without treatment-related side effects, but all were judged to be of poor quality, and the reviewers concluded that BPC-157 "should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials."⁹ An earlier systematic review of the sports-medicine literature found 35 animal studies and 1 clinical study, and "no clinical safety data."¹⁰

FDA's reviewers raised specific concerns about injectable BPC-157, including "the potential for immunogenicity ... due to the potential for aggregation as well as potential peptide-related impurities", and found "a lack of evidence to support the effectiveness of BPC-157" for the condition reviewed.⁷ Questions about cancer risk are covered in our BPC-157 and cancer article.

The others

For KPV, MOTS-c and several other peptides, FDA states that it "has not identified any human exposure data."⁸ A 2026 clinical review warned that unapproved injectable peptides "lack established human safety profiles" and listed risks including contamination, manufacturing impurities and inaccurate dosing.¹⁴

What is still unknown about the policy

Until the text is published, these questions have no official answer:

1. Which peptides are included, and whether the list can change.¹²
2. Which forms: injections carry different risks from creams, nasal sprays or tablets. FDA's BPC-157 concerns were about the injectable form.⁷
3. Which conditions pharmacies must meet, such as ingredient sourcing, testing and labelling.
4. Whether side effects must be reported to FDA. Pharmacies that compound for individual patients generally do not report adverse events today.⁷
5. How long the policy lasts, and what happens if FDA later declines to add a peptide to the list.

We will update this guide when the policy is published.

Questions to ask before you start

If a clinician or telehealth service offers you a compounded peptide, these neutral questions help you judge what you are being offered. A prescriber should be able to answer them.

1. Is this peptide FDA-approved for my condition? If not, what human evidence supports using it for my problem, and how strong is it? Ask for the studies.
2. Which pharmacy will make it, and is it licensed in my state? Federal law requires a licensed pharmacist in a state-licensed pharmacy.⁴ FDA has warned telehealth firms for branding drugs with their own name in a way that hid who made them.¹¹ The pharmacy's name should be on the label.
3. Where does the raw peptide come from, and how is each batch tested? Ask whether the ingredient maker is registered with FDA and whether there is a certificate of analysis for the batch. A purity figure alone does not cover sterility or endotoxin, which matter for injections.
4. What side effects should I watch for, and who do I contact? Ask what happens if you have a reaction, and whether the clinic or pharmacy reports problems to FDA. Our side-effects article summarises what users have reported.
5. Is it safe with my health conditions and other medicines? Mention pregnancy or plans for pregnancy, any history of cancer, and every prescription and supplement you take.
6. How will we know if it is working, and when should I stop? Ask what will be measured and over what period.
7. Am I subject to drug testing? If you compete in sport, check the rules before starting.¹⁰

Warning signs

• Claims that a compounded peptide is "FDA-approved" or "the same as" an approved medicine. FDA treats implied sameness as misleading.¹¹
• No real consultation, or no questions about your health history.
• No pharmacy named on the label, or a product labelled "research use only".
• Promises of guaranteed results for injuries, ageing or weight.

If something goes wrong

Stop and contact a doctor if you have a reaction you are worried about; in an emergency, call emergency services. You or your clinician can also report the problem to FDA through MedWatch, FDA's safety reporting programme for "health professionals, patients and consumers."¹² FDA's reviewers found only three reports involving injectable BPC-157 in its database and cautioned that it "cannot make definitive conclusions" from so few.⁷ More reports would help everyone understand the risks.

Frequently asked questions

Can I get BPC-157 through telehealth now?

Not under any new policy yet. As of 26 October 2026, the interim access policy is still under review and has not been published. No peptide reviewed in July 2026 has been added to the 503A Bulks List.¹² Our BPC-157 legal timeline tracks each change.

Would a compounded peptide from a pharmacy be safer than one bought online?

A licensed pharmacy works under state oversight and federal compounding rules, which "research use only" sellers do not.⁴ That may reduce some quality risks, but FDA still does not check compounded drugs before they are sold, and pharmacy compounding does not fix the lack of human evidence.⁵⁹

Does a prescription mean the peptide has been proven to work?

No. A prescription means a clinician has decided to prescribe it. It does not mean FDA has reviewed it. For BPC-157, the human evidence is limited to three small studies of poor quality.⁵⁹

Is this the same as compounded semaglutide?

No. Semaglutide is the active ingredient of FDA-approved medicines, which is one of the routes the law allows for compounding. The peptides discussed here are not part of any approved drug. FDA's separate moves on compounded GLP-1s are covered in our compounded semaglutide and tirzepatide explainer.⁴⁶

Where can I see the policy when it is published?

The OMB review listing will show when the review concludes, and FDA would publish the policy itself.¹ We will update this article and our HHS plan explainer when that happens.